Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $39.2 million.

  • Keros Therapeutics' Total Liabilities fell 1557.63% to $39.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.2 million, marking a year-over-year decrease of 1557.63%. This contributed to the annual value of $44.3 million for FY2024, which is 1724.58% up from last year.
  • Per Keros Therapeutics' latest filing, its Total Liabilities stood at $39.2 million for Q3 2025, which was down 1557.63% from $50.4 million recorded in Q2 2025.
  • Keros Therapeutics' 5-year Total Liabilities high stood at $55.7 million for Q1 2025, and its period low was $7.8 million during Q2 2021.
  • In the last 5 years, Keros Therapeutics' Total Liabilities had a median value of $30.0 million in 2023 and averaged $28.3 million.
  • As far as peak fluctuations go, Keros Therapeutics' Total Liabilities skyrocketed by 16381.78% in 2023, and later crashed by 1557.63% in 2025.
  • Keros Therapeutics' Total Liabilities (Quarter) stood at $12.1 million in 2021, then surged by 143.09% to $29.4 million in 2022, then grew by 28.8% to $37.8 million in 2023, then grew by 17.25% to $44.3 million in 2024, then fell by 11.57% to $39.2 million in 2025.
  • Its Total Liabilities stands at $39.2 million for Q3 2025, versus $50.4 million for Q2 2025 and $55.7 million for Q1 2025.